Deferred Tax Assets, Valuation Allowance of ROCKET PHARMACEUTICALS, INC. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
ROCKET PHARMACEUTICALS, INC. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • ROCKET PHARMACEUTICALS, INC. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $133,085,000, a 3.1% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

ROCKET PHARMACEUTICALS, INC. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $133,085,000 +$4,008,000 +3.1% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $129,077,000 +$20,605,000 +19% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $108,472,000 +$17,209,000 +19% 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q4 2022 $91,263,000 -$2,098,000 -2.2% 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q4 2021 $93,361,000 -$7,222,000 -7.2% 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q4 2020 $100,583,000 +$48,864,000 +94% 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q4 2019 $51,719,000 +$3,925,000 +8.2% 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q4 2018 $47,794,000 +$46,038,000 +2622% 31 Dec 2018 10-K 01 Mar 2021 2020 FY
Q4 2017 $1,756,000 +$1,273,000 +264% 31 Dec 2017 10-K 08 Mar 2019 2018 FY
Q4 2016 $483,000 -$50,708,000 -99% 31 Dec 2016 10-K 08 Mar 2019 2018 FY
Q4 2015 $51,191,000 +$6,313,000 +14% 31 Dec 2015 10-K 16 Mar 2017 2016 FY
Q4 2014 $44,878,000 31 Dec 2014 10-K 23 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.